Bisoprolol for congestive heart failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Bisoprolol for congestive heart failure. / Rosenberg, J.; Gustafsson, F.

I: Expert Opinion on Pharmacotherapy, Bind 9, Nr. 2, 2008, s. 293-300.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rosenberg, J & Gustafsson, F 2008, 'Bisoprolol for congestive heart failure', Expert Opinion on Pharmacotherapy, bind 9, nr. 2, s. 293-300.

APA

Rosenberg, J., & Gustafsson, F. (2008). Bisoprolol for congestive heart failure. Expert Opinion on Pharmacotherapy, 9(2), 293-300.

Vancouver

Rosenberg J, Gustafsson F. Bisoprolol for congestive heart failure. Expert Opinion on Pharmacotherapy. 2008;9(2):293-300.

Author

Rosenberg, J. ; Gustafsson, F. / Bisoprolol for congestive heart failure. I: Expert Opinion on Pharmacotherapy. 2008 ; Bind 9, Nr. 2. s. 293-300.

Bibtex

@article{2ea47460059111deb05e000ea68e967b,
title = "Bisoprolol for congestive heart failure",
abstract = "Background: beta-Blockers are a cornerstone in the treatment of systolic heart failure treatment, but not all beta-blockers are effective or in this setting. Objective: To define the role of bisoprolol, a highly selective beta(1)-antagonist in congestive heart failure due to systolic dysfunction. Methods: Using the keywords 'bisoprolol' and 'heart failure' PubMed and BIOSIS databases were searched for information regarding pharmacology and relevant randomised clinical trials. Supplementary publications were acquired by scrutinising reference lists of relevant papers. Additional information was obtained from the FDA website. Conclusion: Bisoprolol is an effective and well-tolerated first-line beta-blocker for patients with systolic heart failure. The knowledge is primarily based on study patients with moderate-to-severe heart failure from the three CIBIS trials Udgivelsesdato: 2008/2",
author = "J. Rosenberg and F. Gustafsson",
note = "Times Cited: 0ReviewEnglishRosenberg, JFrederiksberg Univ Hosp, Dept Cardiol, Nordre Fasanvej 57-59, DK-2000 Copenhagen, DenmarkCited References Count: 51258OYINFORMA HEALTHCARETELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDLONDON",
year = "2008",
language = "English",
volume = "9",
pages = "293--300",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Bisoprolol for congestive heart failure

AU - Rosenberg, J.

AU - Gustafsson, F.

N1 - Times Cited: 0ReviewEnglishRosenberg, JFrederiksberg Univ Hosp, Dept Cardiol, Nordre Fasanvej 57-59, DK-2000 Copenhagen, DenmarkCited References Count: 51258OYINFORMA HEALTHCARETELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDLONDON

PY - 2008

Y1 - 2008

N2 - Background: beta-Blockers are a cornerstone in the treatment of systolic heart failure treatment, but not all beta-blockers are effective or in this setting. Objective: To define the role of bisoprolol, a highly selective beta(1)-antagonist in congestive heart failure due to systolic dysfunction. Methods: Using the keywords 'bisoprolol' and 'heart failure' PubMed and BIOSIS databases were searched for information regarding pharmacology and relevant randomised clinical trials. Supplementary publications were acquired by scrutinising reference lists of relevant papers. Additional information was obtained from the FDA website. Conclusion: Bisoprolol is an effective and well-tolerated first-line beta-blocker for patients with systolic heart failure. The knowledge is primarily based on study patients with moderate-to-severe heart failure from the three CIBIS trials Udgivelsesdato: 2008/2

AB - Background: beta-Blockers are a cornerstone in the treatment of systolic heart failure treatment, but not all beta-blockers are effective or in this setting. Objective: To define the role of bisoprolol, a highly selective beta(1)-antagonist in congestive heart failure due to systolic dysfunction. Methods: Using the keywords 'bisoprolol' and 'heart failure' PubMed and BIOSIS databases were searched for information regarding pharmacology and relevant randomised clinical trials. Supplementary publications were acquired by scrutinising reference lists of relevant papers. Additional information was obtained from the FDA website. Conclusion: Bisoprolol is an effective and well-tolerated first-line beta-blocker for patients with systolic heart failure. The knowledge is primarily based on study patients with moderate-to-severe heart failure from the three CIBIS trials Udgivelsesdato: 2008/2

M3 - Journal article

VL - 9

SP - 293

EP - 300

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -

ID: 10904942